163.80
前日終値:
$164.47
開ける:
$164.31
24時間の取引高:
1.49M
Relative Volume:
1.21
時価総額:
$18.64B
収益:
$9.54B
当期純損益:
$841.00M
株価収益率:
22.02
EPS:
7.44
ネットキャッシュフロー:
$1.02B
1週間 パフォーマンス:
-0.03%
1か月 パフォーマンス:
-5.58%
6か月 パフォーマンス:
+9.96%
1年 パフォーマンス:
+29.00%
Quest Diagnostics Inc Stock (DGX) Company Profile
DGX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
DGX
Quest Diagnostics Inc
|
163.80 | 18.64B | 9.54B | 841.00M | 1.02B | 7.44 |
![]()
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
![]()
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
![]()
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
![]()
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-02 | 開始されました | Redburn Atlantic | Buy |
2025-03-04 | ダウングレード | Citigroup | Buy → Neutral |
2025-01-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-12-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2024-12-10 | 再開されました | Jefferies | Buy |
2024-10-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
2024-08-28 | 再開されました | Evercore ISI | In-line |
2024-07-10 | アップグレード | Citigroup | Neutral → Buy |
2024-02-26 | 開始されました | Leerink Partners | Market Perform |
2024-02-07 | アップグレード | Jefferies | Hold → Buy |
2024-01-03 | 開始されました | Barclays | Equal Weight |
2023-12-12 | アップグレード | BofA Securities | Neutral → Buy |
2023-06-29 | 開始されました | Piper Sandler | Neutral |
2023-05-02 | ダウングレード | BofA Securities | Buy → Neutral |
2023-04-03 | アップグレード | Citigroup | Sell → Neutral |
2023-01-23 | 開始されました | Evercore ISI | In-line |
2022-11-17 | ダウングレード | Citigroup | Neutral → Sell |
2022-08-22 | 再開されました | Morgan Stanley | Equal-Weight |
2022-04-04 | ダウングレード | Citigroup | Buy → Neutral |
2022-02-23 | ダウングレード | UBS | Buy → Neutral |
2022-02-02 | ダウングレード | Jefferies | Buy → Hold |
2022-01-28 | ダウングレード | Deutsche Bank | Buy → Hold |
2021-05-04 | アップグレード | UBS | Neutral → Buy |
2021-03-12 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2020-10-21 | アップグレード | Argus | Hold → Buy |
2020-07-29 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
2020-07-14 | アップグレード | BofA Securities | Neutral → Buy |
2020-06-09 | アップグレード | Wells Fargo | Underweight → Equal Weight |
2020-06-02 | アップグレード | Deutsche Bank | Hold → Buy |
2020-04-28 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-04-27 | アップグレード | Citigroup | Neutral → Buy |
2020-04-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2020-03-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-01-08 | 開始されました | Wells Fargo | Underweight |
2020-01-07 | ダウングレード | Barclays | Overweight → Equal Weight |
2019-12-19 | アップグレード | BofA/Merrill | Underperform → Neutral |
2019-07-15 | ダウングレード | Goldman | Neutral → Sell |
2019-04-02 | アップグレード | Jefferies | Hold → Buy |
2019-03-18 | 再開されました | Credit Suisse | Neutral |
2019-01-31 | ダウングレード | Argus | Buy → Hold |
2019-01-17 | 開始されました | UBS | Neutral |
2019-01-03 | ダウングレード | BofA/Merrill | Neutral → Underperform |
2018-12-03 | ダウングレード | BofA/Merrill | Buy → Neutral |
2018-11-30 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Quest Diagnostics Inc (DGX) 最新ニュース
Drug Abuse Testing Market Forecast Report and Company Analysis 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad Labs, Medtronic - Yahoo
Quest Diagnostics Declares Quarterly Cash Dividend - Quantisnow
Drug Screening Market Size Worth USD 10.34 Billion by 2034 | CAGR of 4.84% from 2025 to 2034 - GlobeNewswire Inc.
Peering Into Quest Diagnostics's Recent Short Interest - Benzinga
Price Over Earnings Overview: Quest Diagnostics - Benzinga
Quest Diagnostics price target raised to $198 from $190 at BofA - Yahoo Finance
Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings - Yahoo Finance
Quest Diagnostics (DGX): Price Target Increased to $198 by BofA Analyst | DGX Stock News - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest introduces blood test to confirm amyloid brain pathology in Alzheimer’s - Medical Device Network
Quest Diagnostics (NYSE:DGX) Unveils New Alzheimer's Blood Test With Promising Predictive Accuracy - Yahoo Finance
Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease - PR Newswire
Revolutionary Blood Test Transforms Alzheimer's Diagnosis: Quest's New 91%-Accurate Solution - Stock Titan
Here's What to Expect From Quest Diagnostics’ Next Earnings Report - MSN
Quest Diagnostics : To Speak At The 38th Annual J.P. Morgan Healthcare Conference - MarketScreener
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Compensation Up For Quest Diagnostics GC After Earlier Dip - Law360
Quest Diagnostics (DGX) Shares Cross 2% Yield Mark - Nasdaq
Here's What To Expect From Quest Diagnostics’ Next Earnings Report - Barchart.com
Lobbying Update: $80,000 of QUEST DIAGNOSTICS INCORPORATED lobbying was just disclosed - Nasdaq
Quest Diagnostics CEO sells $6.6 million in stock By Investing.com - Investing.com South Africa
Quest Diagnostics CEO sells $6.6 million in stock - Investing.com
Quest Diagnostics SVP Karthik sells $434,350 in stock By Investing.com - Investing.com Canada
Quest Diagnostics SVP Karthik sells $434,350 in stock - Investing.com
Quest Diagnostics' (NYSE:DGX) Dividend Will Be Increased To $0.80 - Yahoo Finance
Ex-Dividend Reminder: Quest Diagnostics, Preferred Bank and Erie Indemnity - Nasdaq
Redburn Atlantic Initiates Quest Diagnostics at Buy With $195 Price Target - MarketScreener
Quest Diagnostics Incorporated (NYSE:DGX) Passed Our Checks, And It's About To Pay A US$0.80 Dividend - Yahoo
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target - Quantisnow
Quest Revolutionizes Cervical Cancer Screening with New Self-Collection Test - Stock Titan
Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025 - Nasdaq
Quest Health Review 2025: Services, Pricing, and Reliability - Healthline
Quest Diagnostics Incorporated (NYSE:DGX) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Is Quest Diagnostics Stock Outperforming the S&P 500? - MSN
SVP for Diagnostic Services Plewman Patrick covered exercise/tax liability with 162 shares, decreasing direct ownership by 0.77% to 20,988 units (SEC Form 4) - Quantisnow
Is Quest Diagnostics Stock Worth Holding Onto Right Now? - MSN
Nephron Research Downgrades Quest Diagnostics to Hold From Buy, $184 Price Target - Marketscreener.com
Is Quest Diagnostics Stock Outperforming The S&P 500? - Barchart.com
Truist maintains hold on Quest Diagnostics stock, $182 target By Investing.com - Investing.com Australia
Quest Diagnostics (DGX) and Google Cloud to Transform Healthcare Data with AI - Insider Monkey
DGX Stock Set to Benefit From New Google Cloud Partnership - MSN
Top 8 AI News Updates Investors Shouldn’t Miss - Insider Monkey
What 9 Analyst Ratings Have To Say About Quest Diagnostics - Benzinga
Earnings Summary: Quest Diagnostics (DGX) reaffirms FY25 guidance - AlphaStreet
Quest Diagnostics Inc (DGX) 財務データ
収益
当期純利益
現金流量
EPS
Quest Diagnostics Inc (DGX) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
KUPPUSAMY KARTHIK | SVP, Clinical Solutions |
Apr 02 '25 |
Sale |
170.00 |
2,555 |
434,350 |
10,575 |
大文字化:
|
ボリューム (24 時間):